New biologic therapies for psoriatic disease.

Kimberly A Bohjanen, Steven E. Prawer

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Psoriasis is a common cutaneous disease that can have a profound effect on an individual's life. New biologic drugs--proteins that are synthesized using recombinant DNA technology to mimic naturally occurring molecules and that selectively target the immune system--have changed the paradigm for treating this disease. We review 4 biologic drugs that are either currently FDA approved or in phase 3 studies: Alefacept (Amevive) and efalizumab (Raptiva), which are T-cell modulators; etanercept (Enbrel), a soluble TNF receptor; and infliximab (Remicade), an anti-TNF monoclonal antibody.

Original languageEnglish (US)
Pages (from-to)34-36
Number of pages3
JournalMinnesota medicine
Volume87
Issue number3
StatePublished - Mar 2004

Fingerprint Dive into the research topics of 'New biologic therapies for psoriatic disease.'. Together they form a unique fingerprint.

Cite this